AP NEWS

2018/19 RNA Therapy Industry: Technologies Enabling Drug Discovery & Development - ResearchAndMarkets.com

January 7, 2019

DUBLIN--(BUSINESS WIRE)--Jan 7, 2019--The “RNA Technologies Enabling Drug Discovery and Development” report has been added to ResearchAndMarkets.com’s offering.

This research service encompasses a comprehensive analysis of RNA therapy industry from the following perspectives:

Industry Drivers and Challenges Technology Snapshot and Trends Clinical Pipeline Analysis Overview of the IP Landscape Innovator Profiles Future Roadmap

The RNA therapy platforms covered include:

Splice-Switching Oligonucletides (SSO) Other Anti-Sense Oligonucleotide (ASO) Aptamers RNA-interference mRNA saRNA

An appendix is included, comprising lists of major industry influencers found in the study.

Key Topics Covered

1 EXECUTIVE SUMMARY

1.1 Research Scope: RNA Therapies Redefining the Healthcare Landscape

1.2 Analysis Framework: Research Core Value

1.3 Research Methodology: Five Steps Towards Success

1.4 Key Findings

2 RNA THERAPIES: INDUSTRY OVERVIEW

2.1 RNA is the Rising Star of Transformative Therapy Platforms

2.2 Industry Accelerators and Challenges

2.3 RNA Delivery: Technology Segmentation

2.4 RNA Therapies: Technology Segmentation

2.5 Molecular Insights Across RNA Therapy

3 TECHNOLOGY TRENDS & CLINICAL PIPELINE

3.1 Alternative Splicing Induced by SSO Therapies

3.2 Clinical Pipeline Analysis for SSO Therapies for SMA and DMD

3.3 Post-transcriptional Modifications by ASO

3.4 Clinical Pipeline Overview for ASO Therapies

3.5 Emerging Clinical Pipeline for ASO Therapies

3.6 Early Phase ASO Therapies

3.7 Inhibition of Ligand Binding by Aptamer

3.8 Clinical Pipeline Analysis for Aptamer Therapies

3.9 Landmark Year for RNA Interference Therapy Platform

3.10 Clinical Analysis of RNA Interference Therapeutics

3.11 Overview of the Emerging Landscape for mRNA Therapies

3.12 Clinical Pipeline Analysis of mRNA Therapies

3.13 saRNA: The Rising Participant in RNA-based Therapies

4 OVERVIEW OF THE PATENT LANDSCAPE

4.1 Patenting Trends for ASO Technologies

4.2 Patenting Trends for RNAi Platforms

4.3 Patenting Trends for mRNA Technologies

5 INNOVATION PROFILES

5.1 Targeted RNAi Technology for Enhanced Disease Management

5.2 Enabling Targeted Delivery of RNAi Therapeutics

5.3 Developing Stable and Non-immunogenic mRNA Therapies

5.4 Fueling Novel RNA Therapy and Delivery Platforms

5.5 Enabling Potent Antisense Therapeutics

6 FUTURE PERSPECTIVES

6.1 RNA Platforms likely to Transform the Future of Health & Wellness

6.2 Navigating Through The Future Landscape for RNA Technologies

7 GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

7.1 Growth Opportunity 1: ASO Therapies

7.2 Growth Opportunity 2: RNAi Therapies

7.3 Growth Opportunity 3: mRNA Therapies

7.4 Strategic Imperatives for Success and Growth

8 KEY INDUSTRY INFLUENCERS

8.1 Industry Interactions

For more information about this report visit https://www.researchandmarkets.com/research/sdp425/201819_rna?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190107005827/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/07/2019 11:50 AM/DISC: 01/07/2019 11:50 AM

http://www.businesswire.com/news/home/20190107005827/en

AP RADIO
Update hourly